Evidence map›Paper›PMID 39898046›Full record

ArticleiScience2025

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.

Jamie L Lim, Stine Marie Jensen, Jaap J Plomp, Bernhardt Vankerckhoven, Christa Kneip, Rani Coppejans, Christophe Steyaert, Kathleen Moens, Lieselot De Clercq, Martijn R Tannemaat and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Muscles (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jamie L LimDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Stine Marie JensenDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Jaap J PlompDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Bernhardt Vankerckhovenargenx, Zwijnaarde, Belgium.
Christa Kneipargenx, Zwijnaarde, Belgium.
Rani Coppejansargenx, Zwijnaarde, Belgium.
Christophe Steyaertargenx, Zwijnaarde, Belgium.
Kathleen Moensargenx, Zwijnaarde, Belgium.
Lieselot De Clercqargenx, Zwijnaarde, Belgium.
Martijn R TannemaatDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Peter Ulrichtsargenx, Zwijnaarde, Belgium.
Karen Silenceargenx, Zwijnaarde, Belgium.
Silvère M van der MaarelDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Dana L E VergoossenDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Roeland Vanhauwaertargenx, Zwijnaarde, Belgium.
Jan J VerschuurenDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Maartje G HuijbersDepartment of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle-specific kinase (MuSK) orchestrates the establishment and maintenance of neuromuscular synapses. Autoantibodies targeting MuSK cause myasthenia gravis (MG), a disease characterized by skeletal muscle weakness. MuSK autoantibodies are predominantly IgG4 which are bispecific, functionally monovalent antibodies that are antagonists of MuSK signaling. We hypothesized that bivalent MuSK agonist antibodies can rescue MuSK MG. Here, we investigated whether ARGX-119, a MuSK frizzled-like domain agonist antibody, can ameliorate disease in passive transfer models induced by polyclonal patient IgG4. ARGX-119 improved survival and muscle weakness in a mouse model induced by one patient material, but not by three others. Patient-specific efficacy could not be explained by titer or competition for ARGX-119 binding, but rather correlated with the presence of MuSK activating antibodies in some patients. This first proof of concept of a MuSK agonist in a clinically relevant MuSK MG model forms a starting point for therapeutic studies toward ARGX-119 efficacy in neuromuscular diseases.

Indexed as

Biological sciencesHealth sciencesImmune system disorderImmunologyMedical specialtyMedicineNatural sciences

Identifiers

PMID39898046
PMCPMC11783450

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.